Table 1 |
||
|
Structural parameters of trabecular bone, static indices of bone turnover and biochemical bone turnover measures |
||
|
Parameter |
Men |
Women |
|
|
||
|
BV/TV (%) |
10.7 ± 4.0 |
9.8 ± 3.8 |
|
BS/BV (mm2/mm3) |
22.1 ± 6.5 |
24.9 ± 8.5 |
|
Tb.N (number/mm) |
1.1 ± 0.3 |
1.1 ± 0.3 |
|
Tb.Sp (μm) |
900 ± 300 |
900 ± 300 |
|
Tb.Th (μm) |
100 ± 30 |
100 ± 30 |
|
OS/BS (%) |
5.6 ± 7.2 |
8.2 ± 10.5 |
|
ES/BS (%) |
2.3 ± 1.9 |
2.0 ± 1.2 |
|
Serum total RANKL (pmol/l) |
1,091 ± 781 |
1,688 ± 2471 |
|
Serum OPG (pmol/l) |
7.4 ± 2.0 |
7.4 ± 2.8 |
|
Serum ALP (U/l) |
92.9 ± 32.7 |
90.9 ± 19.7 |
|
Serum OCN (μg/l) |
6.0 ± 3.7 |
5.8 ± 2.9 |
|
Urinary DPD (nmol/mmol creatinine) |
18.3 ± 7.4 |
28.9 ± 7.5 |
|
Urinary PYR (nmol/mmol creatinine) |
73.7 ± 27.7 |
102.7 ± 33.7 |
|
|
||
|
Results are expressed as mean ± standard deviation. ALP, alkaline phosphatase; BS/BV, specific surface of bone relative to bone tissue volume; BV/TV, bone volume fraction relative to bone tissue volume; DPD, deoxypyridinoline; ES/BS, eroded surface; OCN, osteocalcin; OPG, osteoprotegerin; OS/BS, osteoid surface; PYR, pyridinoline; RANKL, receptor activator of nuclear factor-κB ligand; Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness. |
||
|
Findlay et al. Arthritis Research & Therapy 2008 10:R2 doi:10.1186/ar2348 |
||
